Difference between revisions of "Tebentafusp (Kimmtrak)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== Bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 10...") |
Warner-admin (talk | contribs) |
||
| (8 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
Bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. | Bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. | ||
| − | == | + | ==Diseases for which it is used== |
| − | + | *[[Uveal melanoma]] | |
| − | + | ||
| + | ==History of changes in FDA indication== | ||
| + | *2022-01-25: Approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic [[uveal melanoma]]. ''(Based on IMCgp100-202)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | *2022-04-01: Initial authorization as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic [[uveal melanoma]]. | ||
| + | ==Also known as== | ||
| + | *'''Code name:''' IMC-gp100 | ||
| + | *'''Generic name:''' tebentafusp-tebn | ||
| + | *'''Brand name:''' Kimmtrak | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Intravenous medications]] | ||
| + | [[Category:Uveal melanoma medications]] | ||
| + | |||
| + | [[Category:Immunotherapeutic]] | ||
| + | [[Category:EMA approved in 2022]] | ||
| + | [[Category:FDA approved in 2022]] | ||
Latest revision as of 00:43, 29 July 2023
Mechanism of action
Bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells.
Diseases for which it is used
History of changes in FDA indication
- 2022-01-25: Approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. (Based on IMCgp100-202)
History of changes in EMA indication
- 2022-04-01: Initial authorization as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Also known as
- Code name: IMC-gp100
- Generic name: tebentafusp-tebn
- Brand name: Kimmtrak